113 related articles for article (PubMed ID: 6376746)
61. Technique of bone marrow transplantation.
Humble JG; Barrett AJ
Proc R Soc Med; 1975 Sep; 68(9):580-2. PubMed ID: 1105599
[No Abstract] [Full Text] [Related]
62. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
63. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
[TBL] [Abstract][Full Text] [Related]
64. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulfan and cyclophosphamide. First results.
Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):403-8. PubMed ID: 2480281
[TBL] [Abstract][Full Text] [Related]
65. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.
Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Bone Marrow Transplant; 1997 Dec; 20(11):909-13. PubMed ID: 9422468
[TBL] [Abstract][Full Text] [Related]
66. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
67. Bone marrow transplantation for thalassemia in Thailand.
Issaragrisil S; Visudhisakchai S; Suvatte V; Chandanayingyong D; Piankijagum A; Mahasandana C; Tanphaichitr VS
Bone Marrow Transplant; 1993; 12 Suppl 1():42-4. PubMed ID: 8374559
[TBL] [Abstract][Full Text] [Related]
68. [Letter: Chronic familial granulomatosis. Treatment using bone marrow graft (1 case)].
Delmas Y; Goudemand J; Farriaux JP
Nouv Presse Med; 1975 Oct; 4(32):2334-5. PubMed ID: 1101217
[No Abstract] [Full Text] [Related]
69. The development of busulfan/cyclophosphamide preparative regimens.
Santos GW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
[TBL] [Abstract][Full Text] [Related]
70. Allogeneic bone marrow transplantation for chronic granulomatous disease.
Rappeport JM; Newburger PE; Goldblum RM; Goldman AS; Nathan DG; Parkman R
J Pediatr; 1982 Dec; 101(6):952-5. PubMed ID: 6754900
[No Abstract] [Full Text] [Related]
71. Chronic granulomatous disease and other disorders of neutrophil function.
Kamani NR; Infante AJ
Clin Rev Allergy Immunol; 2000 Oct; 19(2):141-56. PubMed ID: 11107499
[No Abstract] [Full Text] [Related]
72. Malignancy: X-Linked Cytochrome B Positive Chronic Granulomatous Disease treated by Bone Marrow Transplantation.
Di Bartolomeo P; Papalinetti G; Olioso P; Di Girolamo G; Bavaro P; De Mattia D; Manzionna MM; Schettini F; Torlontano G
Hematology; 1999; 4(4):313-318. PubMed ID: 11399572
[TBL] [Abstract][Full Text] [Related]
73. Long-term follow-up and prognosis of chronic granulomatous disease in Yugoslavia: is there a role for early bone marrow transplantation?
Pasic S; Minic A; Minic P; Veljkovic D; Lilic D; Slavkovic B; Pejnovic N; Abinun M
J Clin Immunol; 2003 Jan; 23(1):55-61. PubMed ID: 12645860
[TBL] [Abstract][Full Text] [Related]
74. Chronic granulomatous disease.
Johnston RB; Newman SL
Pediatr Clin North Am; 1977 May; 24(2):365-76. PubMed ID: 323805
[No Abstract] [Full Text] [Related]
75. Bone marrow transplantation for chronic granulomatous disease associated with cytochrome B deficiency.
Schettini F; De Mattia D; Manzionna MM; Seger RA; Fumarulo R; Torlontano G; Iacone A
Pediatr Hematol Oncol; 1987; 4(3):277-9. PubMed ID: 3152933
[No Abstract] [Full Text] [Related]
76. Future of Care for Patients With Chronic Granulomatous Disease: Gene Therapy and Targeted Molecular Medicine.
Keller MD; Notarangelo LD; Malech HL
J Pediatric Infect Dis Soc; 2018 May; 7(suppl_1):S40-S44. PubMed ID: 29746676
[TBL] [Abstract][Full Text] [Related]
77. Esophageal graft versus host disease.
Khan ZAW; Khan SS; Al-Kaabi S; Ammar AA
Indian J Gastroenterol; 2021 Feb; 40(1):91-93. PubMed ID: 33417174
[No Abstract] [Full Text] [Related]
78. Kx: its relationship to chronic granulomatous disease and genetic linkage with Xg.
Densen P; Wilkinson-Kroovand S; Mandell GL; Sullivan G; Oyen R; Marsh WL
Blood; 1981 Jul; 58(1):34-7. PubMed ID: 7236890
[TBL] [Abstract][Full Text] [Related]
79. Current therapy for chronic granulomatous disease.
Naumovski L; Smith SD
J Pediatr; 1989 Jun; 114(6):1066. PubMed ID: 2498491
[No Abstract] [Full Text] [Related]
80. Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up.
Kamani N; August CS; Campbell DE; Hassan NF; Douglas SD
J Pediatr; 1988 Oct; 113(4):697-700. PubMed ID: 3050003
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
